Gencurix Signs Final Merger Agreement with Genofix, Confirming Small-Scale Merger with 3.17% Dilution

Gencurix has finalized the merger process by signing the absorption merger agreement with Genofix, an unlisted company. The previously disclosed merger ratio of 1 to 5.3591461 and the issuance of 742,456 new shares remain unchanged, resulting in a 3.17% dilution relative to outstanding shares.
As a small-scale merger, appraisal rights are not granted, but if opposing shareholders exceed 20%, the merger may convert to a general merger. The new shares are subject to a one-year lock-up period.
Genofix reported total assets of approximately 200 million KRW, total liabilities of 15 million KRW, and a net loss of 120 million KRW in the latest fiscal year, posing potential financial burdens post-merger. However, synergies are expected from securing liquid biopsy technology and medical networks.
The largest shareholder of Gencurix remains CEO Jo Sang-rae with no change after the merger, indicating stable governance.
[AI Summary]This amendment is an administrative step to replace the merger agreement with a signed version, with no changes to the merger terms or financial figures. The small-scale merger is confirmed with a 3.17% dilution, and Genofix's zero revenue and loss-making structure may pose risks post-integration. The realization of synergies will be key to stock price performance.